Nasolin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nasolin

This section provides a factual overview of the identity, composition, and general purpose of Nasolin (Xylometazoline), adhering strictly to non-commercial and regulatory standards.

Property Description
Active Ingredient Xylometazoline
Form Aqueous Solution (Nasal Drops/Spray)
Pharmacological Class Sympathomimetic; Alpha-adrenergic Agonist
Common Use Relief of Nasal Congestion
Origin Synthetic Compound

What Type of Decongestant is Nasolin?

Nasolin is a medicinal product primarily intended to relieve congestion, and its key active ingredient is Xylometazoline. Pharmacologically, it is classified as a sympathomimetic agent, a category of drugs that mimic the action of substances like adrenaline on the body's nervous system. More specifically, Xylometazoline is defined as an alpha-adrenergic agonist, which is the receptor type it stimulates. It is used to reduce congestion associated with conditions like the common cold or allergic rhinitis.

The medication is a synthetic compound belonging to the imidazoline derivatives chemical class. This classification denotes the core chemical structure responsible for the drug’s distinct vasoconstricting properties. Xylometazoline's action is generally rapid, making it a choice for individuals seeking short-term relief from the feeling of a severely blocked nose.


Composition and Form: The Topical Nasal Solution

The active substance is Xylometazoline, typically formulated as the hydrochloride salt, and it is a single-ingredient preparation. Nasolin is designed as an aqueous solution for topical nasal administration, delivered either as a nasal spray or in the form of nasal drops. This localized application ensures the compound is concentrated directly on the nasal lining, making its effects targeted. Xylometazoline is a local vasoconstrictor.

Nasolin is commonly available as an Over-the-Counter (OTC) product, positioning it as an accessible solution for symptomatic relief. Its aqueous solution is often buffered to maintain a pH balance compatible with the nasal mucosa, a typical formulation detail designed to enhance patient comfort during administration.


General Purpose: How Xylometazoline Provides Relief

The overall purpose of Xylometazoline is to provide temporary relief from the feeling of a blocked or stuffy nose. This is achieved through the physical process of vasoconstriction. By narrowing the small blood vessels (capillaries) in the nasal lining, the drug rapidly decreases the blood flow to the congested area. This immediate reduction in blood volume causes the swollen nasal mucosa to physically shrink. This physical shrinkage is the fundamental benefit of the medication, clearing the obstructed air passages and enabling easier breathing.

What side effects are possible with Nasolin?

Possible Side Effects and Safety Information

The safety profile of Nasolin (Xylometazoline) is officially documented by regulatory authorities, with adverse reactions generally categorized by frequency and the body system affected.

Frequency-Classified Adverse Reactions

The most frequently reported effects are related to the site of application. Common side effects include nasal dryness, discomfort, a burning or stinging sensation in the nose and throat, sneezing, and nausea. Less frequently, Uncommon effects include nosebleeds (epistaxis) and an increase in the swelling of the nasal lining after the medication is stopped.

Systemic effects, which are more likely with prolonged or excessive use, are classified as Rare or Very Rare. These include Rare effects such as palpitations, increased heart rate (tachycardia), and high blood pressure (hypertension). Very Rare effects noted in official documentation include irregular heart rhythms (arrhythmia), hallucinations, and, particularly in infants and neonates, apnoea.

Safety Patterns and Constraints

A critical safety pattern tied to duration of use is the explicit risk of rebound congestion (Rhinitis medicamentosa), which involves an increased swelling of the nasal mucosa following chronic, prolonged, or excessive application. This effect is documented as an Uncommon adverse reaction.

The medication is subject to high-level safety constraints. It is officially contraindicated in patients with conditions such as narrow-angle glaucoma and rhinitis sicca (chronic dry nasal inflammation). Caution is necessary for patients with pre-existing conditions, including hypertension, coronary artery disease, hyperthyroidism, and diabetes mellitus, due to the potential for systemic effects.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Xylometazoline overdose describes systemic effects primarily involving the central nervous and cardiovascular systems. Overdose manifestations may include Central Nervous System (CNS) depression ranging from drowsiness and stupor to profound coma. Cardiovascular effects often present with bradycardia (slow heart rate) and a significant drop in blood pressure (hypotension), which may follow an initial hypertension phase. Other documented signs include tremor, nausea, vomiting, and hypothermia.

Severe, life-threatening consequences are possible, including a shock-like syndrome and profound respiratory depression (decreased breathing). Management is focused on symptomatic and supportive treatment under medical supervision, as no specific antidote is known. Hospital monitoring and observation are required for serious adverse events.

A crucial population-specific consideration is the significant risk to children 5 years of age and younger. Accidental ingestion of even a small amount of the nasal solution by infants and young children can lead to severe systemic toxicity.

If accidental ingestion or suspected overdose occurs, emergency medical care must be sought immediately. Regulatory guidance instructs users to call the Poison Help Line (or equivalent emergency services) for immediate instruction.

Therapeutic Uses of Nasolin

Nasolin (Xylometazoline) is a product commonly used across domains where short-term symptomatic assistance is needed for nasal congestion. It is primarily applied in contexts where additional management of discomfort is required, helping to support functional comfort. The medication is considered relevant for easing congestion due to colds, hay fever, and other respiratory allergies.

The medication is applied in clinical settings that involve acute or disruptive symptom patterns, such as the common cold or influenza, to help address symptom clusters that may become intense or disruptive. It supports the temporary clearance of nasal passages, which may assist with preserving functional comfort during periods of heightened physical discomfort.

Nasolin is relevant in conditions characterized by periods of heightened symptoms like allergic rhinitis and other recurrent manifestations that involve significant mucosal swelling. It contributes to improved day-to-day comfort during symptomatic flare-ups.

This product is also used in situations involving certain distressing symptoms such as sinus pressure and aural ear fullness. When applied appropriately, it contributes to easing the overall symptom load associated with these connected discomforts.

Therapeutic Focus: Acute Nasal Obstruction and Secondary Sinus Pressure

Regulatory References

  1. NIH DailyMed official label information

Eligibility and Restrictions for Use

Who Can and Cannot Use Nasolin (Xylometazoline)?

The eligibility for Nasolin is determined by official regulatory documents, defining specific patient populations who are approved for use, restricted, or strictly prohibited from using the medicine.

Contraindicated Populations

Nasolin is absolutely contraindicated and must not be used in patients diagnosed with Narrow-angle glaucoma, Rhinitis sicca (atrophic rhinitis), or Phaeochromocytoma. Use is also prohibited following trans-sphenoidal hypophysectomy or other surgical procedures exposing the dura mater. Furthermore, the medicine is contraindicated in individuals who have used a Monoamine Oxidase Inhibitor (MAOI) in the last 14 days.

Age-Related Eligibility

The 0.1% concentration is approved for adults and adolescents ge 12 years. The medicine is contraindicated for children under mathbf12 years for the adult strength, and safety is not established for infants under mathbf2 years of age.

Conditional Use and Restrictions

Caution is required for patients with pre-existing systemic conditions, including Hypertension, Cardiovascular disease, Diabetes mellitus, Hyperthyroidism, and Long QT syndrome. Use is not recommended during pregnancy and should be used during lactation only with medical advice.

What should I know about interactions with other medicines?

This section outlines the documented interactions for the active substance in Nasolin, which is a sympathomimetic agent with the potential for systemic effects.

Major Interactions: Contraindicated Combinations

Co-administration is strictly restricted due to the potential for a severe hypertensive crisis (dangerously high blood pressure). This is a pharmacodynamic interaction where the sympathomimetic action is dangerously enhanced.

  • Monoamine Oxidase Inhibitors (MAOIs): Use is restricted if a patient is currently taking an MAOI or has taken one within the previous 14 days. This applies to irreversible MAOIs (e.g., phenelzine, tranylcypromine) and certain reversible agents or related drugs (e.g., linezolid).
  • Ergot Derivatives and Iobenguane I 123: Official regulatory documents also categorize co-use with certain ergot derivatives (e.g., ergotamine) and Iobenguane I 123 as combinations to avoid.

Moderate Interactions: Use with Caution

The following products require careful monitoring due to the risk of additive effects on the cardiovascular system, which may lead to increased blood pressure and heart rate:

  • Tricyclic Antidepressants (TCAs): The vasopressor effect of Nasolin may be potentiated by TCAs (e.g., amitriptyline, imipramine).
  • Other Sympathomimetics: Combining with other medicinal products that stimulate adrenergic receptors (e.g., some bronchodilators, other decongestants) increases the risk of additive pressor effects.
  • Other Drugs Affecting Blood Pressure: Caution is warranted when used with agents like guanethidine or certain antihypertensives, where the drug may decrease the antihypertensive's efficacy.

Mechanism of Action

Nasolin (oxymetazoline) is a direct-acting sympathomimetic agent that primarily targets the vascular network within the nasal mucosa. Its molecular action is that of an agonist at alpha1 and alpha2 adrenergic receptors, with a higher affinity for alpha1-adrenoceptors.

Upon administration to the nasal tissue, the molecule binds to and activates these receptors expressed on the vascular smooth muscle cells of the resistance and capacitance blood vessels (arterioles and venules). Activation of the alpha1-adrenoceptor subtype, a Gq-protein coupled receptor, initiates the intracellular cascade involving phospholipase C and a subsequent increase in intracellular Ca^2+ concentration. This Ca^2+ signal drives the contraction of the vascular smooth muscle, resulting in vasoconstriction. The alpha2-adrenoceptor agonism, acting via Gi-protein coupling, also contributes to this vasoconstriction by inhibiting adenylyl cyclase, which modulates the intracellular cyclic AMP levels.

The downstream cascade is a systemic reduction in the diameter of the nasal microvasculature. The physiological consequence of this localized action is a decrease in local blood flow to the nasal mucosa and a reduction in the hydrostatic pressure, which collectively modulates the volume of the nasal mucosal tissue.

Dosage and Administration Information

How Nasolin (Xylometazoline) is Used: Official Administration Guidelines

Nasolin, which contains Xylometazoline hydrochloride, is administered according to a precise, defined protocol focusing on the topical intranasal route. The medication is provided as an aqueous solution in forms such as nasal drops or a metered-dose nasal spray.


Official Dosing and Frequency

Administration is strictly limited by concentration, dose, and time interval to ensure proper use, as detailed in regulatory documents.

Age Group Concentration Dose and Frequency Use Restrictions
Adults and Children 12 years and older 0.1% solution 1 to 2 sprays or 2 to 3 drops per nostril. Not to exceed 3 doses in any 24-hour period.
Children 6 to 11 years 0.05% solution 1 to 2 sprays or 2 to 3 drops per nostril. Requires adult supervision.
Children < 6 years Not recommended Requires consultation; only the 0.05% strength may be authorized in some regions. Use is generally restricted or contraindicated.

Duration and Administration Protocol

The treatment is designed for short-term use only. Official instructions mandate that Nasolin must not be used for more than 3 to 7 consecutive days. If usage is prolonged beyond this period, a risk of recurring or worsening nasal congestion exists.

Before administration, the nose should be cleared thoroughly to maximize contact with the nasal lining. Dosing must respect a minimum interval of 8 to 12 hours between applications. For hygiene, regulatory guidelines emphasize that each container should be used by only one person to prevent the spread of infection.

Recent Clinical Evidence

Research evidence / Overview of studies for Nasolin (Xylometazoline)

This overview summarizes the official research evidence for Xylometazoline, focusing on the types of studies conducted and the patterns observed, without providing clinical advice or treatment recommendations.


Evidence for Nasal Congestion Caused by the Common Cold

Research examining Nasolin in studies of short-term nasal congestion, often linked to the common cold, was conducted primarily through short-term, randomized controlled trials (RCTs). These studies typically involved adults and explored how symptoms change over time when using Xylometazoline compared to an inactive treatment (placebo). Researchers used both objective physiological measurements, such as instruments that assess nasal airflow, and patient-reported outcomes describing perceived discomfort and stuffiness.

In these studies, researchers recorded measurable changes in nasal airflow following administration of the compound. Trials monitored short-term symptom changes and often reported an association between measured changes in airflow and patient-reported outcomes describing perceived discomfort. The evidence contributes to understanding symptom patterns, with trials focusing on episodes where symptoms become more noticeable and tracking responses over defined time intervals, usually for a few hours up to 10 days of use.

What remains less characterized are the long-term effects of the compound beyond the short-term use explored in efficacy trials. Follow-up durations were limited, and studies provide limited insight into whether Xylometazoline impacts the overall duration or course of a common cold illness.

Evidence for Nasal Congestion Related to Allergies

Research examined measurements taken during the study period, and reported an association with changes in outcomes related to physical discomfort during acute allergic flare-ups. The evidence landscape includes limited information on the long-term or maintenance management of allergic rhinitis, as the studies were conducted during periods of increased symptom activity and do not explore long-term management strategies.

Research Gaps and Areas of Uncertainty

The main research gap concerns the long-term effects of Xylometazoline; the duration of most efficacy studies was limited, meaning sustained effects are not well characterized. Other limitations include variability in findings across studies, particularly those concerning outcomes related to physical discomfort like pain or overall nasal obstruction. Comparative evidence is lacking for certain congestion symptoms. Overall, the available research provides insight into short-term changes and episodic relief but only reflects the group patterns observed under the specific conditions under which the studies were conducted.

Key Studies & References

  1. Xylometazoline Hydrochloride Nasal Solution Official Label and Drug Information (NIH DailyMed)
  2. Alpha-adrenergic agonist (MedlinePlus Drug Information)
  3. Systematic review and meta-analysis of the effectiveness of xylometazoline in reducing acute nasal congestion

Frequently Asked Questions (FAQ)

Common questions about Nasolin (FAQ)


Q: What is the main difference between Nasolin and over-the-counter nasal sprays?

Official information classifies Nasolin (Xylometazoline) as a sympathomimetic and an alpha-adrenergic agonist. This means it is a drug that mimics the action of certain natural substances on the nervous system to specifically cause blood vessels to narrow. This classification describes the specific group of medicines and the type of receptor it acts upon to reduce nasal congestion.


Q: Does Nasolin help with nasal congestion or just other allergy symptoms?

Regulatory documents state that Nasolin is used for the temporary relief of nasal congestion linked to conditions like the common cold, hay fever, and other respiratory allergies. Its use is officially indicated for the congestion that results from allergic conditions.


Q: How long does the effect of one dose of Nasolin typically last?

Official guidelines specify that re-dosing should not occur more often than once every 8 to 12 hours. This interval reflects the typical period that patients can expect the effects to last.


Q: If I miss a dose of Nasolin, what is the general guidance?

General patient information advises that if a dose is missed, patients may take it as soon as it is remembered. However, if the time is close to the next scheduled dose, skipping the missed dose and returning to the regular schedule is described as the appropriate course of action. Official guidance specifies that doses should not be doubled to make up for a missed application.


Q: What is the purpose of the inactive ingredients listed in Nasolin?

Official labels list inactive ingredients such as purified water, buffers, and preservatives. These components serve various purposes, including maintaining the product's stability, ensuring it stays sterile, and helping to maintain a pH level that is comfortable for the nasal lining during administration.


Q: Are there specific instructions for the first time I use a Nasolin bottle?

Yes, regulatory administration guidelines often recommend that the nasal spray device must first be primed before the initial use. This involves pumping or spraying the device into the air several times until a fine mist appears. This ensures that the correct dose will be delivered when the product is administered.


Q: Can Nasolin be used for year-round allergies?

Official guidance mandates that Nasolin is intended for short-term use only, typically 3 to 7 consecutive days. Prolonged or continuous use, such as for year-round symptoms, exceeds the defined short-term usage window and is associated with an increased risk of rebound congestion (Rhinitis medicamentosa).


Q: How quickly do the effects of Nasolin usually start?

Official information indicates the drug has a rapid action because it works directly on the blood vessels in the nasal lining. Available patient information suggests that relief from congestion typically begins quickly, often within 5 to 10 minutes of administration.


Q: Is Nasolin considered safe for long-term use?

Regulatory documents explicitly mandate that the product must not be used for more than 7 consecutive days. This time restriction defines its intended short-term safety window. This restriction is based on the documented risk of rebound congestion (Rhinitis medicamentosa) associated with prolonged use beyond the specified short-term duration.


Q: Is it normal to feel dryness or irritation after using Nasolin?

Yes. According to regulatory documents that list adverse reactions, side effects such as nasal dryness, discomfort, or a burning/stinging sensation in the nose and throat are classified as Common. This means they are known, documented effects that occur frequently according to regulatory reports.


Q: Does using Nasolin affect your sense of taste or smell?

Official regulatory lists of known side effects for Nasolin do not commonly include changes to the senses of taste or smell.


Q: Is there a generic version of Nasolin available?

Yes. Regulatory product listings confirm that the active ingredient in Nasolin, Xylometazoline hydrochloride, is available in the market as an unbranded, generic product.


Q: What does the official drug information say about the duration of a treatment cycle?

Official regulatory documents place a strict restriction on the total length of time the product can be used. The maximum treatment duration is specified as not more than 3 to 7 consecutive days to mitigate known risks.


Q: Can Nasolin be used to treat symptoms of a common cold?

Official indications specify that Nasolin is used to provide temporary relief of one main symptom of the common cold: nasal congestion. It is not indicated for treating other cold symptoms like fever, body aches, or sore throat.


Q: What is the mechanism of action of Nasolin described as in regulatory documents?

Regulatory documents describe the active ingredient as an alpha-adrenergic agonist. This substance acts by stimulating specific receptors, which leads to the small blood vessels in the nasal lining narrowing (vasoconstriction). The physical result of this narrowing is a reduction in swelling, which helps clear the air passages.


Q: Is Nasolin associated with any effects on eye pressure?

The medication is strictly contraindicated (must not be used) in patients who have been diagnosed with a specific condition involving increased eye pressure, known as narrow-angle glaucoma. This link is officially documented under product safety information.


Q: Does Nasolin have official warnings about use in people with glaucoma?

Yes. Narrow-angle glaucoma is listed as an absolute contraindication in the regulatory documents, meaning its use is entirely prohibited for individuals with this condition.


Q: Are there special considerations for using Nasolin in older adults?

Official patient information states that caution is required when the drug is used in elderly patients. This is specifically noted for older adults who have pre-existing conditions such as cardiac disease, diabetes mellitus, or high blood pressure.


Q: Is Nasolin a product that should be shaken before use?

The specific product's administration protocol specifies whether the device needs to be shaken before each use. Patients should always refer to the specific instructions provided with their particular product to ensure correct administration.


Q: Can using Nasolin affect my ability to drive or operate machinery?

Regulatory documents often state that Nasolin has no or negligible influence on the ability to drive and use machines. However, if any systemic effects such as dizziness or drowsiness are experienced, caution is warranted.


Q: Is Nasolin a medication that can expire, and what happens if it's used past the date?

Yes, regulatory information defines a shelf life for the sealed product and an in-use stability period (e.g., 28 days) after opening. Official storage instructions note that medicine should be disposed of after its printed expiration date or in-use stability period to maintain product quality and efficacy.


Q: Can I use Nasolin if I have asthma?

Asthma is not listed as a contraindication for use in the regulatory documents. However, regulatory warnings indicate that caution is required for patients with certain underlying respiratory conditions.


Q: Are there clinical trials that have examined Nasolin in relation to sinus issues?

Yes, official regulatory indications specify that Nasolin is used for the relief of nasal congestion associated with conditions including sinusitis. This means its use has been evaluated in contexts involving sinus congestion.


Q: Does Nasolin interact with common blood thinners?

The official interactions list focuses on medicines that may cause additive effects on the cardiovascular system, such as MAOIs and tricyclic antidepressants. The regulatory list does not explicitly name or detail interactions with common blood thinners (anticoagulants or antiplatelets).


Q: Are there reports of headache as a side effect of Nasolin?

Yes. Regulatory documents that list known side effects classify headache as a Common side effect for Nasolin. This means it is a known adverse reaction that has been frequently reported during use.

How should Nasolin be stored and disposed of?

How to Store and Dispose of Nasolin?

The official storage and disposal requirements for Nasolin (Xylometazoline) are strictly defined in regulatory labeling to maintain the product's quality and ensure safety.


Storage Requirements

  • Temperature: Store the product at room temperature, typically 20°C to 25°C (68°F to 77°F). It is directed not to store above 25°C.
  • Container and Protection: Keep the medicine in the original container, tightly closed. The carton should be retained for full labeling reference.
  • Stability: The in-use stability of the nasal spray is brand-dependent; some labels advise not using the bottle for more than 28 days after opening.
  • Child Safety: It is mandatory to keep out of the sight and reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

Disposal Instructions

Any unused product or waste material should be disposed of in accordance with local requirements. The medicine should not be thrown away via wastewater or household waste unless specifically directed by local disposal rules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nasolin found in:

A-Z Index: